Drug Combination Details
| General Information of the Combination (ID: C58370) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [2] | |||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [3] | |||
|
Lip/oral cavity/pharynx neoplasm
[ICD-11: 2B6E]
|
Investigative | [4] | |||
|
Adenocarcinoma
[ICD-11: 2D40]
|
Investigative | [5] | |||
|
Metastatic lymph node neoplasm
[ICD-11: 2D60]
|
Investigative | [6] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AR | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDKN2A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | Erbb-4 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HIF-1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NFKBIB | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | ||
| IGROV-1 | CVCL_1304 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| R182 | Ovarian cancer | Homo sapiens | ||||
| Experimental
Result(s) |
Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CLU | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction. | |||||
| Experiment 3 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HSC-2 | CVCL_1287 | Oral cavity squamous cell carcinoma | Homo sapiens | ||
| HSC-3 | CVCL_1288 | Tongue squamous cell carcinoma | Homo sapiens | |||
| HSC-4 | CVCL_1289 | Tongue squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. | |||||
| Experiment 4 Reporting the Effect of This Combination | [6] | |||||
| Molecule(s)
Regulation |
Down-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IVL | Molecule Info | |||
| Down-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NANOG | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | POU5F1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SAS | CVCL_1675 | Tongue squamous cell carcinoma | Homo sapiens | ||
| OECM-1 | CVCL_6782 | Gingival squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | To establish nude mouse transplantation tumor model, HN-CICs cells were subcutaneously injected into BALB/c nude mice (6-8 weeks). | |||||
| Experimental
Result(s) |
Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK/STAT3 signaling on targeting head and neck cancer Initiating cells. | |||||
| Experiment 5 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Activity | HK2 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | To establish nude mouse transplantation tumor model, 0.5* 106 ehrlich ascites carcinoma cells were injected in the female BALB/c mice. | |||||
| Experimental
Result(s) |
Combination of arsenic trioxide and cisplatin synergistically inhibits both hexokinase activity and viability of Ehrlich ascites carcinoma cells. | |||||
| Experiment 6 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Elevation | [Ca(2+)](i) concentration | ||||
| In-vitro Model | SH-SY5Y | CVCL_0019 | Neuroblastoma | Homo sapiens | ||
| Experimental
Result(s) |
Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells shows additive effects. | |||||
